← 프로그램 목록
세포·유전자 치료Phase 2Recruiting

Autologous immune Cells

Liaoning Medical DiagnosisTreatment Technology ResearchDevelopment Co.Ltd.

비교

Autologous immune Cells(Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.)은 Lung Cancer (Locally Advanced or Metasta 표적 세포·유전자 치료로, Lung Cancer (Locally Advanced or Metastatic); Liver Cancer (Locally Advanced or Metastatic) 영역에서 개발·상용화 중입니다. 작용기전: checkpoint co-expression score correlated with both overall and contact-dependent tumor cell death. Phase 2에서 효능·안전성 신호를 검증 중입니다. OS: 16. 차별점: novel treatment approach aiming to increase precision and reduce toxicity compared with traditional immune checkpoint inhibit.

출처: ClinicalTrials.gov · PubMed · openFDA최근 동기화됨

개요

임상 2026년 7월 13일 (1일 전)PK/독성 2026년 7월 13일 (1일 전)

Lung Cancer (Locally Advanced or Metasta

Lung Cancer (Locally Advanced or Metastatic); Liver Cancer (Locally Advanced or Metastatic)

Recruiting

Technology

NK cell activation in MDOTS when combined with TGFβ and PD-1

design

Lentiviral vectors encoding murine or human IL6/1 were designed using Vector Builder and e

novel treatment approach aiming to increase precision and reduce toxicity compared with traditional immune checkpoint inhibit

Mechanism of Action

checkpoint co-expression score correlated with both overall and contact-dependent tumor cell death

T-cell activation

apoptosis through soluble inflammatory mediators in a same-donor primary-cell system

biomarkers and therapeutic targets for investigating tumor-specific immune responses following locoregional t

downregulation of inflammation-related pathways, whereas another allogeneic donor strain induced a distinct transcriptional profile

임상시험 & 결과

차트 로드 중…

임상 한눈에 보기

  • 31건의 ClinicalTrials.gov 임상 기록
  • Phase·Status 요약은 enrollment 상위 표본 기준입니다
  • 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
  • Phase: Phase 2, Phase 3 · Phase 3 · Phase 2 · Phase 1, Phase 2…
  • Status: Recruiting · Active, not recruiting · Unknown status
  • 주요 endpoint: Successful optimisation of a scRNAseq protocol using dissociated human bowel cells · Survival · Progression-free survival · Overall Survival (OS) · Progression-free Survival (PFS)
  • 핵심: RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. I…

임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.

참고문헌

자주 묻는 질문

Autologous immune Cells은 어떤 치료제인가요?
Autologous immune Cells(Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.)은 Lung Cancer (Locally Advanced or Metasta 표적 세포·유전자 치료로, Lung Cancer (Locally Advanced or Metastatic); Liver Cancer (Locally Advanced or Metastatic) 영역에서 개발·상용화 중입니다. 데이터는 바이오모아 (BioMoa)에서 ClinicalTrials.gov·openFDA·PubMed 기반으로 정리합니다.
Autologous immune Cells의 임상 단계는?
Autologous immune Cells의 현재 단계는 Phase 2입니다.
비슷한 프로그램과 어떻게 비교하나요?
바이오모아 (BioMoa) 비교 페이지에서 PK/PD, 독성, 임상 효능 지표를 나란히 볼 수 있습니다. 동일 타깃·모달리티 프리셋을 함께 참고하세요.